The 2022-2026 Workplan of the Accelerate Clinical Trials in the EU (ACT EU) initiative has been published by the European Commission (EC), the Heads of Medicines Agencies (HMA), and the European Medicines Agency (EMA).
The ACT EU, launched on January 2022, seeks to promote the development of high-quality, safe, and effective medicines by strengthening the European clinical trials environment, whilst maintaining the high level of protection of trial participants, data robustness, and transparency that EU citizens expect. The workplan is structured in line with the ten priority actions of ACT EU and highlights key focus areas, such as innovation in clinical trials, robust methodologies, and collaboration across stakeholders.
The ACT EU workplan has been prepared based on the recommendations of the EMA network strategy for 2025 and the EC’s Pharmaceutical Strategy for Europe.
More information about the ACT EU is available here.